Lyell Immunopharma Initiates Phase 3 Clinical Trial for LYL314 in Relapsed or Refractory Large B-Cell Lymphoma
Lyell Immunopharma, Inc. has announced the initiation of two pivotal-stage clinical trials for its product candidate LYL314. The trials will focus on patients with large B-cell lymphoma (LBCL) who have relapsed or are refractory to two or more lines of prior therapy. The company plans to submit a Biologics License Application for LYL314 later in 2027, following the expected data from the LYL314 PiNACLE pivotal trial. Additionally, Lyell is set to conduct a Phase 3 randomized controlled trial for LYL314 in the second-line setting for relapsed or refractory LBCL patients. Furthermore, the company intends to begin a clinical trial evaluating a new internally-developed CAR T-cell therapy targeting an undisclosed solid tumor. Results from these trials are anticipated in the future, with a clinical trial data update from LYL314 expected by the end of this year.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lyell Immunopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-164853), on July 25, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。